In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

(MedPage Today) -- Replacing two high-dose chemotherapy courses with blinatumomab (Blincyto) significantly improved event-free survival (EFS) in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), an interim...